{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pandel+Cream+0.1%25", "query": { "intervention": "Pandel Cream 0.1%" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T00:40:21.941Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02465606", "title": "A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 55, "start_date": "2015-07-30", "completion_date": "2016-05-30", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 12, "location_summary": "Encino, California • Granada Hills, California • Mission Viejo, California + 9 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465606" }, { "nct_id": "NCT00693693", "title": "Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "hydrocortisone 17-butyrate 0.1% Cream preparation", "type": "DRUG" }, { "name": "hydrocortisone 17-butyrate 0.1% Ointment preparation", "type": "DRUG" }, { "name": "hydrocortisone 17-butyrate 0.1% Lipocream preparation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-11", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693693" }, { "nct_id": "NCT02260986", "title": "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" }, { "name": "Topical Corticosteroid (TCS)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2014-09", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02260986" }, { "nct_id": "NCT03568318", "title": "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Topical corticosteroids (TCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 1533, "start_date": "2018-08-09", "completion_date": "2030-10-23", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568318" }, { "nct_id": "NCT03539601", "title": "A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Crisaborole ointment, 2%", "type": "DRUG" }, { "name": "Hydrocortisone butyrate cream, 0.1%", "type": "DRUG" }, { "name": "Pimecrolimus cream, 1%", "type": "DRUG" }, { "name": "Crisaborole Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 237, "start_date": "2018-04-27", "completion_date": "2020-12-11", "has_results": true, "last_update_posted_date": "2022-01-10", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 10, "location_summary": "Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more", "locations": [ { "city": "Bryant", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03539601" }, { "nct_id": "NCT02340234", "title": "A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "TCS Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 212, "start_date": "2015-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 16, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340234" }, { "nct_id": "NCT01137032", "title": "Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "Pandel Cream 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fougera Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": 19, "start_date": "2004-06", "completion_date": "2005-08", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-09-24T00:40:21.941Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Hilton Head Island", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137032" } ] }